MX2019014192A - Inhibidor de inmunosupresion asociado al cancer. - Google Patents
Inhibidor de inmunosupresion asociado al cancer.Info
- Publication number
- MX2019014192A MX2019014192A MX2019014192A MX2019014192A MX2019014192A MX 2019014192 A MX2019014192 A MX 2019014192A MX 2019014192 A MX2019014192 A MX 2019014192A MX 2019014192 A MX2019014192 A MX 2019014192A MX 2019014192 A MX2019014192 A MX 2019014192A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- associated immunosuppression
- inhibitor
- immunosuppression inhibitor
- glyco
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a un compuesto portador de fragmento Fc modificado mediante glicoingeniería para su uso como un inhibidor de inmunosupresión en el tratamiento de una inmunosupresión asociada a cáncer. La invención se refiere además a una composición farmacéutica que comprende por lo menos este compuesto portador de fragmento Fc modificado mediante glicoingeniería.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17305619 | 2017-05-29 | ||
PCT/EP2018/064081 WO2018219956A1 (en) | 2017-05-29 | 2018-05-29 | Cancer-associated immunosuppression inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019014192A true MX2019014192A (es) | 2021-04-12 |
Family
ID=59054051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019014192A MX2019014192A (es) | 2017-05-29 | 2018-05-29 | Inhibidor de inmunosupresion asociado al cancer. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200148777A1 (es) |
EP (1) | EP3630826A1 (es) |
JP (2) | JP2020521780A (es) |
KR (1) | KR20200031571A (es) |
CN (1) | CN111108123A (es) |
BR (1) | BR112019025352A8 (es) |
CA (1) | CA3064333A1 (es) |
MX (1) | MX2019014192A (es) |
WO (1) | WO2018219956A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110023337B (zh) | 2016-10-11 | 2024-01-05 | 艾吉纳斯公司 | 抗lag-3抗体及其使用方法 |
CN114716558B (zh) * | 2022-04-12 | 2023-05-05 | 骏蓦(北京)生物科技有限公司 | 一种双特异性抗体及其治疗癌症的应用 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
EP2322644A1 (en) | 2000-06-28 | 2011-05-18 | GlycoFi, Inc. | Methods for producing modified glycoproteins |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
EP1959018B1 (en) | 2002-03-19 | 2011-05-11 | Stichting Dienst Landbouwkundig Onderzoek | Optimizing glycan processing in plants |
AU2005259221B2 (en) | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
EP1888649A2 (en) * | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
PL2439273T3 (pl) | 2005-05-09 | 2019-08-30 | Ono Pharmaceutical Co., Ltd. | Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami |
JP2008541770A (ja) * | 2005-06-03 | 2008-11-27 | ジェネンテック・インコーポレーテッド | 改変したフコシル化レベルを有する抗体の産生方法 |
NZ596322A (en) | 2006-01-17 | 2013-02-22 | Synthon Biopharmaceuticals Bv | Compositions and methods for humanization and optimization of N-glycans in duckweed plants |
US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
EP4169951A1 (en) | 2008-12-09 | 2023-04-26 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
EP2459594A1 (en) | 2009-07-31 | 2012-06-06 | N.V. Organon | Fully human antibodies to btla |
AU2010286361A1 (en) | 2009-08-31 | 2012-03-15 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
CN104961829B (zh) | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
FR2959994B1 (fr) | 2010-05-12 | 2012-08-24 | Lfb Biotechnologies | Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii |
PT2707391T (pt) * | 2011-05-13 | 2018-02-06 | Inserm Institut National De La Santa© Et De La Rech Ma©Dicale | Anticorpos contra her3 |
WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
US9422351B2 (en) | 2011-11-03 | 2016-08-23 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
FR2984750B1 (fr) * | 2011-12-23 | 2014-01-10 | Lfb Biotechnologies | Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii |
MX2015014773A (es) * | 2013-04-22 | 2016-03-04 | Glycotope Gmbh | Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja. |
CA2929386C (en) * | 2013-11-07 | 2023-01-03 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Neuregulin allosteric anti-her3 antibody |
FR3020063A1 (fr) * | 2014-04-16 | 2015-10-23 | Gamamabs Pharma | Anticorps humain anti-her4 |
CN106659774A (zh) * | 2014-05-16 | 2017-05-10 | 贝勒研究院 | 用于治疗自身免疫和炎性病症的方法和组合物 |
EP3331569A1 (en) * | 2015-08-07 | 2018-06-13 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
US9630575B2 (en) | 2015-09-30 | 2017-04-25 | GM Global Technology Operations LLC | Panel assembly with noise attenuation system |
-
2018
- 2018-05-29 JP JP2019565843A patent/JP2020521780A/ja active Pending
- 2018-05-29 KR KR1020197038406A patent/KR20200031571A/ko not_active Application Discontinuation
- 2018-05-29 EP EP18727015.2A patent/EP3630826A1/en active Pending
- 2018-05-29 CN CN201880048764.4A patent/CN111108123A/zh active Pending
- 2018-05-29 BR BR112019025352A patent/BR112019025352A8/pt unknown
- 2018-05-29 MX MX2019014192A patent/MX2019014192A/es unknown
- 2018-05-29 WO PCT/EP2018/064081 patent/WO2018219956A1/en active Application Filing
- 2018-05-29 CA CA3064333A patent/CA3064333A1/en active Pending
- 2018-05-29 US US16/617,136 patent/US20200148777A1/en active Pending
-
2022
- 2022-09-26 JP JP2022153137A patent/JP2023073965A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023073965A (ja) | 2023-05-26 |
WO2018219956A1 (en) | 2018-12-06 |
RU2019137534A (ru) | 2021-06-30 |
RU2019137534A3 (es) | 2021-11-01 |
BR112019025352A8 (pt) | 2023-05-02 |
CN111108123A (zh) | 2020-05-05 |
EP3630826A1 (en) | 2020-04-08 |
KR20200031571A (ko) | 2020-03-24 |
BR112019025352A2 (pt) | 2020-08-18 |
JP2020521780A (ja) | 2020-07-27 |
US20200148777A1 (en) | 2020-05-14 |
CA3064333A1 (en) | 2018-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022001165A (es) | Composiciones terapeuticas, combinaciones y metodos de uso. | |
MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
MX2021002455A (es) | Metodos para tratar tumores de celulas epitelioides. | |
MX2018012016A (es) | Compuestos biciclicos. | |
MX2019011496A (es) | Composiciones de niraparib. | |
MX2018002986A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos. | |
MX2018001990A (es) | Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac. | |
NZ739676A (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
MY189454A (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
PH12016501702B1 (en) | Pyrazole amide derivative | |
NZ725917A (en) | Novel polymerase-i inhibitors, uses and methods for making them | |
MX2017004808A (es) | Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple. | |
MX2020001793A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
MX2022010755A (es) | Inhibidores de quinasa y usos de los mismos. | |
MX2017007188A (es) | Compuesto antimicotico. | |
EP4234552A3 (en) | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
PH12018500504A1 (en) | Compounds useful for inhibiting ror-gamma-t | |
EP4306173A3 (en) | Compositions and methods for treating cancers | |
MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
MX2019014192A (es) | Inhibidor de inmunosupresion asociado al cancer. | |
PH12017501601A1 (en) | Use of isolated fractions of mastic gum for treating optic neuropathy | |
MA40027A (fr) | Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique |